Free Newsletter
MIT scientists reverse autism, retardation in mice
Researchers from the Picower Institute for Learning and Memory at Massachusetts Institute of Technology have reversed mild retardation and severe autism in mice by inhibiting the enzyme called p21-activated kinase (PAK). Their study focused on Fragile X Syndrome (FXS)--a leading cause of retardation and autism--which is linked to a mutated X chromosome gene. The PAK enzyme controls the connections between neurons and the brain.
"Strikingly, PAK inhibition also restored electrical communication between neurons in the brains of the FXS mice, correcting their behavioral abnormalities in the process," co-author Susumu Tonegawa, 1987 Nobel laureate and Picower Professor of Biology and Neuroscience, said in a prepared statement. "Notably, due to an elegant genetic manipulation of method employed by the Picower Institute researchers, PAK inhibition in the FXS mice did not take place until a few weeks after appearance of disease symptoms. This implies that future treatment may still be effective even after symptoms are already pronounced."
- read the report from Forbes
Related Article:
Potential breakthrough made for Down syndrome. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: